These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
532 related articles for article (PubMed ID: 17484215)
1. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Reisinger KS; Block SL; Lazcano-Ponce E; Samakoses R; Esser MT; Erick J; Puchalski D; Giacoletti KE; Sings HL; Lukac S; Alvarez FB; Barr E Pediatr Infect Dis J; 2007 Mar; 26(3):201-9. PubMed ID: 17484215 [TBL] [Abstract][Full Text] [Related]
2. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women. McCormack PL; Joura EA BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919 [TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine. Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885 [TBL] [Abstract][Full Text] [Related]
4. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women. McCormack PL; Joura EA Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263 [TBL] [Abstract][Full Text] [Related]
5. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial. Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Hillman RJ; Giuliano AR; Palefsky JM; Goldstone S; Moreira ED; Vardas E; Aranda C; Jessen H; Ferris DG; Coutlee F; Marshall JB; Vuocolo S; Haupt RM; Guris D; Garner EI Clin Vaccine Immunol; 2012 Feb; 19(2):261-7. PubMed ID: 22155768 [TBL] [Abstract][Full Text] [Related]
7. Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine: for the prevention of genital warts in males. Garnock-Jones KP; Giuliano AR Drugs; 2011 Mar; 71(5):591-602. PubMed ID: 21443282 [TBL] [Abstract][Full Text] [Related]
8. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Villa LL; Costa RL; Petta CA; Andrade RP; Paavonen J; Iversen OE; Olsson SE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; Krogh Gv; Lehtinen M; Malm C; Tamms GM; Giacoletti K; Lupinacci L; Railkar R; Taddeo FJ; Bryan J; Esser MT; Sings HL; Saah AJ; Barr E Br J Cancer; 2006 Dec; 95(11):1459-66. PubMed ID: 17117182 [TBL] [Abstract][Full Text] [Related]
9. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial. Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002 [TBL] [Abstract][Full Text] [Related]
10. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. ; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284 [TBL] [Abstract][Full Text] [Related]
11. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls. Vesikari T; Brodszki N; van Damme P; Diez-Domingo J; Icardi G; Petersen LK; Tran C; Thomas S; Luxembourg A; Baudin M Pediatr Infect Dis J; 2015 Sep; 34(9):992-8. PubMed ID: 26090572 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial. Poland GA; Jacobson RM; Koutsky LA; Tamms GM; Railkar R; Smith JF; Bryan JT; Cavanaugh PF; Jansen KU; Barr E Mayo Clin Proc; 2005 May; 80(5):601-10. PubMed ID: 15887427 [TBL] [Abstract][Full Text] [Related]
13. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women. Ruiz-Sternberg ÁM; Moreira ED; Restrepo JA; Lazcano-Ponce E; Cabello R; Silva A; Andrade R; Revollo F; Uscanga S; Victoria A; Guevara AM; Luna J; Plata M; Dominguez CN; Fedrizzi E; Suarez E; Reina JC; Ellison MC; Moeller E; Ritter M; Shields C; Cashat M; Perez G; Luxembourg A Papillomavirus Res; 2018 Jun; 5():63-74. PubMed ID: 29269325 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects. Kang S; Kim KH; Kim YT; Kim YT; Kim JH; Song YS; Shin SH; Ryu HS; Han JW; Kang JH; Park SY Int J Gynecol Cancer; 2008; 18(5):1013-9. PubMed ID: 17986242 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial. Sharma H; Parekh S; Pujari P; Shewale S; Desai S; Bhatla N; Joshi S; Pimple S; Kawade A; Balasubramani L; Thomas A; Suri V; Lalwani S; Uday R; Kamath V; Mandal R; Rajeswar A; Peedicayil A; Poli UR; Banerjee D; Sankaranarayanan R; Basu P; Muwonge R; Gairola S; Dogar V; Rao H; Shaligram U Lancet Oncol; 2023 Dec; 24(12):1321-1333. PubMed ID: 37949086 [TBL] [Abstract][Full Text] [Related]
16. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years. Schwarz TF; Huang LM; Valencia A; Panzer F; Chiu CH; Decreux A; Poncelet S; Karkada N; Folschweiller N; Lin L; Dubin G; Struyf F Hum Vaccin Immunother; 2019; 15(7-8):1970-1979. PubMed ID: 31268383 [TBL] [Abstract][Full Text] [Related]
17. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ; MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109 [TBL] [Abstract][Full Text] [Related]
18. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565 [TBL] [Abstract][Full Text] [Related]
19. The prophylactic role for the human papillomavirus quadrivalent vaccine in males. Yancey AM; Pitlick JM; Forinash AB Ann Pharmacother; 2010; 44(7-8):1314-8. PubMed ID: 20501891 [TBL] [Abstract][Full Text] [Related]
20. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]